Cellares to provide proof-of-concept manufacturing for a key BMS CAR-T cell therapy Cellares' proprietary Cell Shuttle is a cost-efficient, reliable, fully automated, and highly scalable manufacturing ...

Technology Adoption Program (TAP) program success demonstrates the ability of Cellares’ IDMO Smart Factory to automate, lower costs and scale out manufacturing for Cabaletta Bio’s clinical-stage CAR T ...

Cellares, an Integrated Development and Manufacturing Organization (IDMO), concluded the Technology Adoption Program (TAP) on its automated cell therapy manufacturing Cell Shuttle™ for resecabtagene ...

Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell Shuttle Collaboration to evaluate potential utilization of the Cell Shuttle ...

Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell Shuttle Collaboration to evaluate potential utilization of the Cell Shuttle ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...